Methods: MEDLINE, In-Process & Other Non-Indexed Citations, and EMBASE Drugs & Pharmacology were searched using olizumab, omalizumab, E25, rhuMAb-E25, and anti-IgE. Combinations of rhinitis ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 domain of immunoglobulin E (IgE) and forms ... in children, the drug is indicated for patients ...

On Friday, the US Food and Drug Administration (FDA) approved as the first interchangeable biosimilar to Swiss pharma giant ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...

Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV ...

“We believe we are at the forefront of an emerging field to design drugs based on ... demonstrate that an IgE protease achieved comparable efficacy to an approved anti-IgE therapy in animal ...